---
title: "Exact Sciences Earnings Review: Q4 Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275948367.md"
description: "Exact Sciences (NASDAQ:EXAS) reported Q4 earnings on February 13, 2026, missing estimates by 362.5% with an EPS of $-0.21 against an expected $0.08. Revenue increased to $164.96 million compared to the previous year. In the prior quarter, the company exceeded EPS estimates by $0.09, leading to a 3.9% rise in share price. Historical performance shows fluctuations in EPS and revenue across previous quarters. For more details, visit their earnings calendar."
datetime: "2026-02-13T21:08:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275948367.md)
  - [en](https://longbridge.com/en/news/275948367.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275948367.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275948367.md) | [繁體中文](https://longbridge.com/zh-HK/news/275948367.md)


# Exact Sciences Earnings Review: Q4 Summary

The Q4 earnings report for **Exact Sciences** (NASDAQ:EXAS) was released on Friday, February 13, 2026 at 04:05 PM.

Here's what investors need to know about the latest announcement.

### Earnings

Exact Sciences missed estimated earnings by -362.5%, reporting an EPS of $-0.21 versus an estimate of $0.08.

Revenue was up $164.96 million from the same period last year.

### Performance in Previous Earnings

In the previous quarter, the company beat on EPS by $0.09, resulting in a 3.9% increase change in the share price the following day.

Here's a look at Exact Sciences's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

0.15

0.02

\-0.37

\-0.31

**EPS Actual**

0.24

\-0.01

\-0.21

\-0.06

**Revenue Estimate**

810.51M

774.43M

689.35M

701.30M

**Revenue Actual**

850.74M

811.09M

706.78M

713.42M

To track all earnings releases for Exact Sciences visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Exact Sciences Corporation (EXAS.US)](https://longbridge.com/en/quote/EXAS.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Healthcare Providers ETF (IHF.US)](https://longbridge.com/en/quote/IHF.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Genomics Immnlgy & Hlthcr ETF (IDNA.US)](https://longbridge.com/en/quote/IDNA.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX](https://longbridge.com/en/news/281318320.md)
- [Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/281385092.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/en/news/281233412.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md)